TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31484565

Group type: EXPERIMENTAL
Intervention: Low-dose information program with follow-up email support and resources including an activity tracker (Fitbit) for 3 months and free trial class at the university sports facility
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study: 28269804

Group type: EXPERIMENTAL
Intervention: Exercise training program (3 times a week for 11 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 25455589

Group type: EXPERIMENTAL
Intervention: Active tDCS with neurocognitive training (PASAT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham tDCS with neurocognitive training (PASAT)
Number of subjects: 33
Study: 23642953

Group type: EXPERIMENTAL
Intervention: Needling with bi-directional rotation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Deep needling (2 cm)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Superficial needling (0.3 cm)
Number of subjects: 53
Study: 21081834

Group type: EXPERIMENTAL
Intervention: Statin treatment (pravastatin 10 mg/day, fluvastatin 20 mg/day, pitavastatin 1 mg/day, atorvastatin 10 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (non-statin-treated group with LDL-C < 140 mg/dL)
Number of subjects: 114
Study: 19339325

Group type: EXPERIMENTAL
Intervention: ATM intervention (money management program)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control intervention (completion of a simple financial workbook)
Number of subjects: 85
Study: 16762939

Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt (experimental group)
Number of subjects: 1981

Group type: COMPARATOR
Intervention: Regular salt (control group)
Number of subjects: 1981
Study: 15686669

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 20
Study: 11735093

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 8 weeks
Number of subjects: 24
Study: 9161941

Group type: EXPERIMENTAL
Intervention: Intraexaminer measurements
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interexaminer measurements
Number of subjects: 50
Study: 8260300

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Pancuronium (neuromuscular blocker)
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alcuronium (neuromuscular blocker)
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 1257
Study: 2888937

Group type: EXPERIMENTAL
Intervention: Neuroleptics (chlorprothixene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranquilizers (diazepam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychostimulants (caffeine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypoxidotics/nootropics (pyritinol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31436372

Group type: EXPERIMENTAL
Intervention: Physical activity (Actical activity monitor)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 68
Study: 29771080

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid monotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intratympanic corticosteroid monotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combination therapy (IT plus systemic corticosteroid)
Number of subjects: 98

Group type: COMPARATOR
Intervention: All groups combined (systemic, IT, and combination therapy)
Number of subjects: 98
Study: 26845463

Group type: EXPERIMENTAL
Intervention: TB-specific quit smoking message delivered by doctors and a TB and smoking educational booklet and quit smoking guide
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ongoing cessation messages delivered by family members trained to be DOTS supporters
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both arms of the study
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 15 patients who shifted from heavy smoking to low-moderate levels post treatment
Number of subjects: 87
Study: 24465955

Group type: EXPERIMENTAL
Intervention: 3 glasses of sparkling white wine (30 g alcohol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: alcohol‐free sparkling white wine
Number of subjects: 28
Study: 22183172

Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine (3TC) once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine (3TC) once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine-triphosphate (3TC-TP) once daily for 10 days
Number of subjects: 24
Study: 18812447

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study: 17485597

Group type: EXPERIMENTAL
Intervention: Candesartan (Atacand, Astra Zeneca), 16 mg o.d. for 12 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 16110036

Group type: EXPERIMENTAL
Intervention: Imatinib (initial dose)
Number of subjects: 934
Study: 11926853

Group type: EXPERIMENTAL
Intervention: Closed, moderated, e-mail discussion group, along with a book and videotape about back pain
Number of subjects: 580

Group type: COMPARATOR
Intervention: Non-health-related magazine subscription (control)
Number of subjects: 580
Study: 9523246

Group type: EXPERIMENTAL
Intervention: Keyboard use in patients with RSI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprathreshold stimulation in patients with RSI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (office workers)
Number of subjects: 0
Study: 7657800

Group type: EXPERIMENTAL
Intervention: Insulin plus fat/heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin plus glycerol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline plus fat/heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin plus fat/heparin (euglycemic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin (euglycemic)
Number of subjects: 0
Study: 2663743

Group type: COMPARATOR
Intervention: Normal carbohydrate‐rich diet (N)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High‐maltodextrin, low‐fructose beverage (Mf)
Number of subjects: 13
Study: 779562

Group type: EXPERIMENTAL
Intervention: DM-prostaglandin E2 capsule (127 mug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DM-prostaglandin E2 liquid (127 mug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DM-prostaglandin E2 capsule
Number of subjects: 0
Study: 31650500

Group type: EXPERIMENTAL
Intervention: Conservative oxygen administration (SpO2 target of 90% with FreeO2 device)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liberal oxygen administration (SpO2 target of ≥ 95% with manual titration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liberal oxygen administration in retainers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liberal oxygen administration in non-retainers
Number of subjects: 30
Study: 30640653

Group type: EXPERIMENTAL
Intervention: Single-injection serratus block with L-bupivacaine 0.25% 30mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 60
Study: 29247513

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 26215480

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33°C
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36°C
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 950

Group type: COMPARATOR
Intervention: Bystander defibrillation
Number of subjects: 950

Group type: COMPARATOR
Intervention: Coronary angiography (CAG) and percutaneous coronary intervention (PCI) <24h after ROSC
Number of subjects: 950
Study: 24142481

Group type: EXPERIMENTAL
Intervention: 6-month cycle ergometer exercise program supervised by primary care nurses (SE group; n = 46)
Number of subjects: 97

Group type: COMPARATOR
Intervention: unsupervised walking program (UW group; n = 51)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison between SE and UW groups
Number of subjects: 97
Study: 22966864

Group type: EXPERIMENTAL
Intervention: HI estrogen phase
Number of subjects: 14

Group type: COMPARATOR
Intervention: LO estrogen phase
Number of subjects: 14
Study: 19620065

Group type: EXPERIMENTAL
Intervention: Insulin plus astragalus
Number of subjects: 84

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 84
Study: 17725919

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study: 15224060

Group type: EXPERIMENTAL
Intervention: Nickel sulfate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Potassium dichromate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Manganese chloride
Number of subjects: 38

Group type: COMPARATOR
Intervention: Orthodontic appliances
Number of subjects: 38
Study: 15876213

Group type: EXPERIMENTAL
Intervention: Lifetime risk estimates of AD based on age, gender, family history, and Apolipoprotein E (APOE) genotype
Number of subjects: 149
Study: 10569127

Group type: EXPERIMENTAL
Intervention: Maintenance Interpersonal Psychotherapy (IPT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Maintenance placebo, nortriptyline, or combination treatment
Number of subjects: 25
Study: 8907290

Group type: EXPERIMENTAL
Intervention: gestodene/30ugEE
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: desogestrel/30ugEE
Number of subjects: 44

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 44

Group type: COMPARATOR
Intervention: dazmegrel (UK38485)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: oral contraceptives
Number of subjects: 44
Study: 1894034

Group type: EXPERIMENTAL
Intervention: Sperm prepared in human tubal fluid (HEPES buffer)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sperm prepared in Ham's F-10 medium (bicarbonate buffer)
Number of subjects: 101
Study: 6411878

Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia
Number of subjects: 21
Study: 30830494

Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Radionovela
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Digital story
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention control group (flu vaccination)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All intervention arms
Number of subjects: 160
Study: 29852043

Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks with docetaxel (80 or 100 mg/m2) followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide
Number of subjects: 2174

Group type: COMPARATOR
Intervention: Trastuzumab for 1 year with identical chemotherapy
Number of subjects: 2174
Study: 27362552

Group type: EXPERIMENTAL
Intervention: Green placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circle placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 24768615

Group type: EXPERIMENTAL
Intervention: Dual tasking (performing a fluency task of listing items in a category)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-task condition (no dual tasking)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levodopa (dopaminergic medication)
Number of subjects: 20
Study: 22649263

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX; 21 g/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (SCF; 21 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No supplemental fiber (NFC)
Number of subjects: 20
Study: 20181812

Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D (1 g elemental Ca as carbonate plus 400 IU vitamin D(3)/d)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259
Study: 18614429

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg (Test)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ciproxin 500 mg (Reference)
Number of subjects: 14
Study: 16336424

Group type: COMPARATOR
Intervention: Cypher stent
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Endeavor stent
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Paclitaxel-releasing stents without polymer
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Paclitaxel released from a polymer
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Sirolimus released from a polymer
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Everolimus released from a polymer
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Biolimus A9 released from a polymer
Number of subjects: 11118

Group type: COMPARATOR
Intervention: Zotarolimus released from a polymer
Number of subjects: 11118
Study: 11919231

Group type: EXPERIMENTAL
Intervention: Early radiotherapy with concurrent chemotherapy (arm I)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Late radiotherapy with chemotherapy (arm II)
Number of subjects: 274
Study: 10342082

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (1 mg)/ethinyl estradiol (35 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate (1 mg)/ethinyl estradiol (20 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 smokers and 10 nonsmokers)
Number of subjects: 60
Study: 7561329

Group type: EXPERIMENTAL
Intervention: Short perfusion group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Long perfusion group
Number of subjects: 26
Study: 1767368

Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 19

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 19
Study: 30996381

Group type: EXPERIMENTAL
Intervention: 3DP custom tray made by independent development chair-side system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Manually conventional method
Number of subjects: 15
Study: 28448590

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation (200 μg Se/day as organic selenium yeast tablets and 200 mg/day of coenzyme Q10 capsules)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 25372556

Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy Eating diet for 6 months
Number of subjects: 120
Study: 23435861

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (n=74)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Filgrastim (n=76)
Number of subjects: 151
Study: 20608950

Group type: EXPERIMENTAL
Intervention: Z-axis video observers
Number of subjects: 128

Group type: COMPARATOR
Intervention: Still image observers
Number of subjects: 128
Study: 19254592

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Oral contraception (OC)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Nonhormonal contraception (NH)
Number of subjects: 703
Study: 16716061

Group type: EXPERIMENTAL
Intervention: SCUBA dive to 4.5 meters for 60 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-immersed 1 ATA SCUBA control exposure
Number of subjects: 10
Study: 15109011

Group type: EXPERIMENTAL
Intervention: Attention group (n = 80) with an empathic provider present during the procedure
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard group (n = 79) receiving standard care
Number of subjects: 159
Study: 11817022

Group type: EXPERIMENTAL
Intervention: Brachytherapy with direct episcleral application of ruthenium applicators
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 42
Study: 9215516

Group type: EXPERIMENTAL
Intervention: Combined antioxidant vitamin capsules providing 400 IU/day vitamin E, 500 mg/day vitamin C, and 6 mg/day beta-carotene
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 8267470

Group type: EXPERIMENTAL
Intervention: Circulatory arrest
Number of subjects: 171

Group type: COMPARATOR
Intervention: Low-flow bypass (50 mL · kg‐1 · min‐1)
Number of subjects: 171
Study: 3302061

Group type: EXPERIMENTAL
Intervention: Combination therapy (ethionamide, rifampicin, or clofazimine with dapsone)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dapsone plus rifampicin combination
Number of subjects: 68

Group type: COMPARATOR
Intervention: Dapsone monotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: All groups (including dapsone monotherapy)
Number of subjects: 68
Study: 31203378

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.06 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exenatide (0.5 μg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.06 mg) with exendin-(9,39) pretreatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Liraglutide and Exenatide
Number of subjects: 63
Study: 27466251

Group type: EXPERIMENTAL
Intervention: Threat condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reduced-threat condition
Number of subjects: 80
Study: 25743734

Group type: EXPERIMENTAL
Intervention: EASE program (3 weeks duration, including a 570-minute group meeting and telephone counseling twice a week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study: 23735098

Group type: EXPERIMENTAL
Intervention: Occupational therapy (18 hours/week for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 60
Study: 21705689

Group type: EXPERIMENTAL
Intervention: Oral palmitoyl-ethanolamide (PEA) 300-mg tablets twice a day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PEA vehicle tablets twice a day)
Number of subjects: 42
Study: 19318297

Group type: EXPERIMENTAL
Intervention: Ephedrine after priming (PE)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo following priming (P)
Number of subjects: 64
Study: 16490490

Group type: EXPERIMENTAL
Intervention: Active PCV
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CNV secondary to AMD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CNV of pathologic myopia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (cataract surgery patients)
Number of subjects: 32
Study: 15871941

Group type: EXPERIMENTAL
Intervention: Service-learning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no service-learning)
Number of subjects: 40
Study: 11273391

Group type: EXPERIMENTAL
Intervention: Self-reported racial prejudice in 1998-1999
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection decisions involving strong or weak qualifications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection decisions involving ambiguous qualifications
Number of subjects: 0
Study: 9330919

Group type: EXPERIMENTAL
Intervention: $5/$10/day incentives for nonmethadone patients
Number of subjects: 142

Group type: COMPARATOR
Intervention: $0 or $1/day incentives for nonmethadone patients
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 142

Group type: COMPARATOR
Intervention: Nonmethadone maintenance
Number of subjects: 142
Study: 8405695

Group type: EXPERIMENTAL
Intervention: Acipimox (slow-release formulation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acipimox (administered every 2 hours for 4 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3530849

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 30690860

Group type: EXPERIMENTAL
Intervention: DBBM + L‐PRF (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: DBBM alone (control)
Number of subjects: 12
Study: 28601864

Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD) 1.34 g/kg body weight
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) 0.8 g/kg body weight
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD) (adherent subgroup)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) (adherent subgroup)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups (HPD and SPD)
Number of subjects: 118
Study: 26661283

Group type: EXPERIMENTAL
Intervention: Doxycycline/hydroxychloroquine for 6 months
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional antibiotic treatments
Number of subjects: 1
Study: 22992332

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 100 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20702510

Group type: EXPERIMENTAL
Intervention: Expanded cardiac rehabilitation
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation
Number of subjects: 224
Study: 19673649

Group type: EXPERIMENTAL
Intervention: Rapid virologic clearance and low-level viremia (HCV RNA level, <400,000 IU/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete viral suppression after 4 weeks of treatment (RVR)
Number of subjects: 0
Study: 16699278

Group type: EXPERIMENTAL
Intervention: Rifaximin-based triple therapy (rifaximin 400 mg t.i.d., esomeprazole 40 mg o.d., clarithromycin 500 mg b.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Levofloxacin-based therapy (levofloxacin 500 mg o.d.)
Number of subjects: 48
Study: 15041399

Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMF 1000 mg b.i.d.
Number of subjects: 0